Conference Coverage: EHA 2026 – Focus on CLL/SLL and NHL
Expert perspectives and strategic insights on the latest therapeutic developments in CLL/SLL and NHL treatment from the EHA 2026 conference.

Faculty Chair
Brad Kahl, MD
Washington University School of Medicine, St Louis, MO, USA
Faculty Members
Marc Hoffmann, MD
University of Kansas, Kansas City, KS, USA
David Russler-Germain, MD, PhD
Washington University, St Louis, MO, USA
Jonathon Cohen, MD
Winship Cancer Institute of Emory University, Atlanta, GA, USA
Julio Chavez, MD
Mayo Clinic, Jacksonville, FL, USA
Renata Walewska, MD, PhD
Royal Bournemouth Hospital, United Kingdom
Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology, Italy
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Advances in
- First-line diffuse large B-cell lymphoma (DLBCL)/aggressive B-cell lymphoma
- Relapsed/refractory (R/R) DLBCL/aggressive B-cell lymphoma
- First-line chronic lymphocytic leukemia (CLL)
- R/R CLL
- Follicular lymphoma
- Mantle cell lymphoma and marginal zone lymphoma
- Attendee key takeaways
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.